CompletedNCT01243242
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
Medication studyAges 18–50Israel
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- Haifa and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateFebruary 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Alcobra Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Israel
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01243242
- Official title
Show the full official title
Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder
Get this study by email
Recruitment & locations
CompletedHaifa · Petah Tikva
Questions about this study
Who is behind this study?
The study sponsor is Alcobra Ltd.
Did this study involve medication?
Yes. The study involved medication, including Metadoxine (MG01CI).
Who was this study for?
Listed age limits: 18 years to 50 years.
